Present and future of developmental neuropsychopharmacology

European Neuropsychopharmacology

Volumn 25, Issue 5, 2015, Pages 703-712

  Arango, Celso ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PSYCHOTROPIC AGENT;

ARTICLE; BRAIN DEVELOPMENT; CHILD PSYCHIATRY; CONSENSUS; EARLY INTERVENTION; HUMAN; INTERVENTION STUDY; LIFESPAN; MENTAL HEALTH; MENTAL HEALTH RESEARCH; NERVE CELL DIFFERENTIATION; PRIMARY PREVENTION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SECONDARY PREVENTION; SUICIDAL IDEATION; ADOLESCENT; BRAIN; CHILD; DRUG EFFECTS; ETHICS; GROWTH, DEVELOPMENT AND AGING; PEDIATRICS; PROCEDURES;

ADOLESCENT; BRAIN; CHILD; HUMANS; PEDIATRICS; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS;

EID: 84928248243     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.11.003     Document Type: Article

References (79)

1. Ahn K., Gotay N., Andersen T.M., Anvari A.A., Gochman P., Lee Y., Sanders S., Guha S., Darvasi A., Glessner J.T., Hakonarson H., Lencz T., State M.W., Shugart Y.Y., Rapoport J.L. High rate of disease-related copy number variations in childhood onset schizophrenia. Mol. Psychiatry 2014, 19:568-572.
2. Amminger G.P., Schafer M.R., Papageorgiou K., Klier C.M., Cotton S.M., Harrigan S.M., Mackinnon A., McGorry P.D., Berger G.E. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2010, 67:146-154.
3. Arango C. Someone is not listening to the facts: there is little psychiatry outside child and adolescent psychiatry. Eur. Child Adolesc. Psychiatry 2012, 21:475-476.
4. Arango C. To treat or not to treat? And how to treat? Two questions whose answers are far removed from evidence informed practice in child psychiatry. Eur. Child Adolesc. Psychiatry 2013, 22:521-522.
5. Arango C., Fraguas D., Parellada M. Differential neurodevelopmental trajectories in patients with early-onset bipolar and schizophrenia disorders. Schizophr. Bull. 2014, 40(Suppl. 2):S138-S146.
6. Barkat T.R., Polley D.B., Hensch T.K. A critical period for auditory thalamocortical connectivity. Nat. Neurosci. 2011, 14:1189-1194.
7. Baudouin S.J., Gaudias J., Gerharz S., Hatstatt L., Zhou K., Punnakkal P., Tanaka K.F., Spooren W., Hen R., De Zeeuw C.I., Vogt K., Scheiffele P. Shared synaptic pathophysiology in syndromic and nonsyndromic rodent models of autism. Science 2012, 338:128-132.
8. Brennand K.J., Simone A., Jou J., Gelboin-Burkhart C., Tran N., Sangar S., Li Y., Mu Y., Chen G., Yu D., McCarthy S., Sebat J., Gage F.H. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011, 473:221-225.
9. Brennand K.J., Simone A., Tran N., Gage F.H. Modeling psychiatric disorders at the cellular and network levels. Mol. Psychiatry 2012, 17:1239-1253.
10. Bridge J.A., Birmaher B., Iyengar S., Barbe R.P., Brent D.A. Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am. J. Psychiatry 2009, 166:42-49.
11. Brown A.S., McGrath J.J. The prevention of schizophrenia. Schizophr. Bull. 2011, 37:257-261.
12. Cabungcal J.H., Counotte D.S., Lewis E.M., Tejeda H.A., Piantadosi P., Pollock C., Calhoon G.G., Sullivan E.M., Presgraves E., Kil J., Hong L.E., Cuenod M., Do K.Q., O'Donnell P. Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia. Neuron 2014, 83:1073-1084.
13. Castro-Fornieles J. Child and adolescent psychiatry: the need for training and development. Revista de psiquiatria y salud mental 2013, 6:57-59.
14. Chao H.T., Chen H., Samaco R.C., Xue M., Chahrour M., Yoo J., Neul J.L., Gong S., Lu H.C., Heintz N., Ekker M., Rubenstein J.L., Noebels J.L., Rosenmund C., Zoghbi H.Y. Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 2010, 468:263-269.
15. Coe B.P., Witherspoon K., Rosenfeld J.A., van Bon B.W., Vulto-van Silfhout A.T., Bosco P., Friend K.L., Baker C., Buono S., Vissers L.E., Schuurs-Hoeijmakers J.H., Hoischen A., Pfundt R., Krumm N., Carvill G.L., Li D., Amaral D., Brown N., Lockhart P.J., Scheffer I.E., Alberti A., Shaw M., Pettinato R., Tervo R., de Leeuw N., Reijnders M.R., Torchia B.S., Peeters H., Thompson E., O'Roak B.J., Fichera M., Hehir-Kwa J.Y., Shendure J., Mefford H.C., Haan E., Gecz J., de Vries B.B., Romano C., Eichler E.E. Refining analyses of copy number variation identifies specific genes associated with developmental delay. Nat. Genet. 2014.
16. Coghill D. Pragmatic measures in paediatric psychopharmacology-are we getting it right?. Eur. Neuropsychopharmacol.: The Journal of the European College of Neuropsychopharmacology 2011, 21:571-583.
17. Collins P.Y., Patel V., Joestl S.S., March D., Insel T.R., Daar A.S., Scientific Advisory B., the Executive Committee of the Grand Challenges on Global Mental H., Anderson W., Dhansay M.A., Phillips A., Shurin S., Walport M., Ewart W., Savill S.J., Bordin I.A., Costello E.J., Durkin M., Fairburn C., Glass R.I., Hall W., Huang Y., Hyman S.E., Jamison K., Kaaya S., Kapur S., Kleinman A., Ogunniyi A., Otero-Ojeda A., Poo M.M., Ravindranath V., Sahakian B.J., Saxena S., Singer P.A., Stein D.J. Grand challenges in global mental health. Nature 2011, 475:27-30.
18. Correll C.U., Gerhard T., Olfson M. Prescribing of psychotropic medications to children and adolescents: quo vadis?. World Psychiatry: Official Journal of the World Psychiatric Association 2013, 12:127-128.
19. Cortese S., Holtmann M., Banaschewski T., Buitelaar J., Coghill D., Danckaerts M., Dittmann R.W., Graham J., Taylor E., Sergeant J., European A.G.G. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry, Allied Disciplines 2013, 54:227-246.
20. Costello E.J., Copeland W., Angold A. Trends in psychopathology across the adolescent years: what changes when children become adolescents, and when adolescents become adults?. J Child Psychol Psychiatry, Allied Disciplines 2011, 52:1015-1025.
21. Cross-Disorder Group of the Psychiatric Genomics C. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013, 381:1371-1379.
22. Diaz-Caneja C.M., Espliego A., Parellada M., Arango C., Moreno C. Polypharmacy with antidepressants in children and adolescents. Int. J. Neuropsychopharmacolog. Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum 2014, 17:1063-1082.
23. Dudley J.T., Sirota M., Shenoy M., Pai R.K., Roedder S., Chiang A.P., Morgan A.A., Sarwal M.M., Pasricha P.J., Butte A.J. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci. Transl. Med. 2011, 3. (96ra76).
24. Duffy A. The nature of the association between childhood ADHD and the development of bipolar disorder: a review of prospective high-risk studies. Am. J. Psychiatry 2012, 169:1247-1255.
25. European Network of National Networks studying Gene-Environment Interactions in S., van Os J., Rutten B.P., Myin-Germeys I., Delespaul P., Viechtbauer W., van Zelst C., Bruggeman R., Reininghaus U., Morgan C., Murray R.M., Di Forti M., McGuire P., Valmaggia L.R., Kempton M.J., Gayer-Anderson C., Hubbard K., Beards S., Stilo S.A., Onyejiaka A., Bourque F., Modinos G., Tognin S., Calem M., O'Donovan M.C., Owen M.J., Holmans P., Williams N., Craddock N., Richards A., Humphreys I., Meyer-Lindenberg A., Leweke F.M., Tost H., Akdeniz C., Rohleder C., Bumb J.M., Schwarz E., Alptekin K., Ucok A., Saka M.C., Atbasoglu E.C., Guloksuz S., Gumus-Akay G., Cihan B., Karadag H., Soygur H., Cankurtaran E.S., Ulusoy S., Akdede B., Binbay T., Ayer A., Noyan H., Karadayi G., Akturan E., Ulas H., Arango C., Parellada M., Bernardo M., Sanjuan J., Bobes J., Arrojo M., Santos J.L., Cuadrado P., Rodriguez Solano J.J., Carracedo A., Garcia Bernardo E., Roldan L., Lopez G., Cabrera B., Cruz S., Diaz Mesa E.M., Pouso M., Jimenez E., Sanchez T., Rapado M., Gonzalez E., Martinez C., Sanchez E., Olmeda M.S., de Haan L., Velthorst E., van der Gaag M., Selten J.P., van Dam D., van der Ven E., van der Meer F., Messchaert E., Kraan T., Burger N., Leboyer M., Szoke A., Schurhoff F., Llorca P.M., Jamain S., Tortelli A., Frijda F., Vilain J., Galliot A.M., Baudin G., Ferchiou A., Richard J.R., Bulzacka E., Charpeaud T., Tronche A.M., De Hert M., van Winkel R., Decoster J., Derom C., Thiery E., Stefanis N.C., Sachs G., Aschauer H., Lasser I., Winklbaur B., Schlogelhofer M., Riecher-Rossler A., Borgwardt S., Walter A., Harrisberger F., Smieskova R., Rapp C., Ittig S., Soguel-dit-Piquard F., Studerus E., Klosterkotter J., Ruhrmann S., Paruch J., Julkowski D., Hilboll D., Sham P.C., Cherny S.S., Chen E.Y., Campbell D.D., Li M., Romeo-Casabona C.M., Emaldi Cirion A., Urruela Mora A., Jones P., Kirkbride J., Cannon M., Rujescu D., Tarricone I., Berardi D., Bonora E., Seri M., Marcacci T., Chiri L., Chierzi F., Storbini V., Braca M., Minenna M.G., Donegani I., Fioritti A., La Barbera D., La Cascia C.E., Mule A., Sideli L., Sartorio R., Ferraro L., Tripoli G., Seminerio F., Marinaro A.M., McGorry P., Nelson B., Amminger G.P., Pantelis C., Menezes P.R., Del-Ben C.M., Gallo Tenan S.H., Shuhama R., Ruggeri M., Tosato S., Lasalvia A., Bonetto C., Ira E., Nordentoft M., Krebs M.O., Barrantes-Vidal N., Cristobal P., Kwapil T.R., Brietzke E., Bressan R.A., Gadelha A., Maric N.P., Andric S., Mihaljevic M., Mirjanic T. Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. Schizophr. Bull. 2014, 40:729-736.
26. Faraone S.V., Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur. Child Adolesc. Psychiatry 2010, 19:353-364.
27. Fenske E.C., Zalenski C., Krantz P.J., McClannahan L.E. Age at intervention and treatment outcome for autistic children in a comprehensive intervention program. Anal. Intervention Dev. Disabil. 1985, 5:49-58.
28. Fraguas D., Correll C.U., Merchan-Naranjo J., Rapado-Castro M., Parellada M., Moreno C., Arango C. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur. Neuropsychopharmacol.: The Journal of the European College of Neuropsychopharmacology 2011, 21:621-645.
29. Fusar-Poli P., Yung A.R., McGorry P., van Os J. Lessons learned from the psychosis high-risk state: towards a general staging model of prodromal intervention. Psychol. Med. 2014, 44:17-24.
30. Gibbons R.D., Brown C.H., Hur K., Davis J., Mann J.J. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch. Gen. Psychiatry 2012, 69:580-587.
31. Gilissen C., Hehir-Kwa J.Y., Thung D.T., van de Vorst M., van Bon B.W., Willemsen M.H., Kwint M., Janssen I.M., Hoischen A., Schenck A., Leach R., Klein R., Tearle R., Bo T., Pfundt R., Yntema H.G., de Vries B.B., Kleefstra T., Brunner H.G., Vissers L.E., Veltman J.A. Genome sequencing identifies major causes of severe intellectual disability. Nature 2014, 511:344-347.
32. Gkogkas C.G., Khoutorsky A., Ran I., Rampakakis E., Nevarko T., Weatherill D.B., Vasuta C., Yee S., Truitt M., Dallaire P., Major F., Lasko P., Ruggero D., Nader K., Lacaille J.C., Sonenberg N. Autism-related deficits via dysregulated eIF4E-dependent translational control. Nature 2013, 493:371-377.
33. Glennon J., Purper-Ouakil D., Bakker M., Zuddas A., Hoekstra P., Schulze U., Castro-Fornieles J., Santosh P.J., Arango C., Kolch M., Coghill D., Flamarique I., Penzol M.J., Wan M., Murray M., Wong I.C., Danckaerts M., Bonnot O., Falissard B., Masi G., Fegert J.M., Vicari S., Carucci S., Dittmann R.W., Buitelaar J.K., The P.C. Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges. Eur. Child Adolesc. Psychiatry 2013.
34. Gross C., Berry-Kravis E.M., Bassell G.J. Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 2012, 37:178-195.
35. Hendren R.L. Autism: biomedical complementary treatment approaches. Child Adolesc. Psychiatr. Clin. N. Am. 2013, 22:443-456. (vi).
36. Henry A., Kisicki M.D., Varley C. Efficacy and safety of antidepressant drug treatment in children and adolescents. Mol. Psychiatry 2012, 17:1186-1193.
37. Hetrick S.E., McKenzie J.E., Cox G.R., Simmons M.B., Merry S.N. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst. Rev. 2012, 11:CD004851.
38. Hollis N.D., Allen E.G., Oliver T.R., Tinker S.W., Druschel C., Hobbs C.A., O'Leary L.A., Romitti P.A., Royle M.H., Torfs C.P., Freeman S.B., Sherman S.L., Bean L.J. Preconception folic acid supplementation and risk for chromosome 21 nondisjunction: a report from the National Down Syndrome Project. Am. J. Med. Genet. Part A 2013, 161A:438-444.
39. Insel T.R. Rethinking schizophrenia. Nature 2010, 468:187-193.
40. Jeste S.S., Geschwind D.H. Disentangling the heterogeneity of autism spectrum disorder through genetic findings. Nat. Rev. Neurol. 2014, 10:74-81.
41. Kessler R.C., Avenevoli S., Costello J., Green J.G., Gruber M.J., McLaughlin K.A., Petukhova M., Sampson N.A., Zaslavsky A.M., Merikangas K.R. Severity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication Adolescent Supplement. Arch. Gen. Psychiatry 2012, 69:381-389.
42. Kleijer K.T., Schmeisser M.J., Krueger D.D., Boeckers T.M., Scheiffele P., Bourgeron T., Brose N., Burbach J.P. Neurobiology of autism gene products: towards pathogenesis and drug targets. Psychopharmacology 2014, 231:1037-1062.
43. Klein D.F. The loss of serendipity in psychopharmacology. JAMA 2008, 299:1063-1065.
44. Linares L.O., Martinez-Martin N., Castellanos F.X. Stimulant and atypical antipsychotic medications for children placed in foster homes. PLoS One 2013, 8:e54152.
45. Lussier Y.A., Chen J.L. The emergence of genome-based drug repositioning. Sci. Transl. Med. 2011, 3. (96ps35).
46. Maibing C.F., Pedersen C.B., Benros M.E., Mortensen P.B., Dalsgaard S., Nordentoft M. Risk of schizophrenia increases after all child and adolescent psychiatric disorders: a nationwide study. Schizophr. Bull. 2014.
47. Mammen G., Faulkner G. Physical activity and the prevention of depression: a systematic review of prospective studies. Am. J. Prev. Med. 2013, 45:649-657.
48. McGorry P. Prevention, innovation and implementation science in mental health: the next wave of reform. Br. J. Psychiatry 2013, Supplement 54:s3-s4.
49. Mehta D., Iwamoto K., Ueda J., Bundo M., Adati N., Kojima T., Kato T. Comprehensive survey of CNVs influencing gene expression in the human brain and its implications for pathophysiology. Neurosci. Res. 2014, 79:22-33.
50. Merchan-Naranjo J., Tapia C., Bailon C., Moreno C., Baeza I., Calvo-Escalona R., Morer A., Martinez-Cantarero C., Nestares P.A., Alda J.A., Munoz D., Arango C. Secondary effects of antipsychotic treatment in naive or quasi-naive children and adolescents: design of a follow-up protocol and baseline results. Revista de Psiquiatria y Salud Mental 2012, 5:217-228.
51. Millan M.J. An epigenetic framework for neurodevelopmental disorders: from pathogenesis to potential therapy. Neuropharmacology 2013, 68:2-82.
52. Moreno C., Arango C., Parellada M., Shaffer D., Bird H. Antidepressants in child and adolescent depression: where are the bugs?. Acta Psychiatr. Scand. 2007, 115:184-195.
53. Moreno C., Hasin D.S., Arango C., Oquendo M.A., Vieta E., Liu S., Grant B.F., Blanco C. The bipolar-depressive continuum in the National Epidemiologic Survey on Alcohol and Related Conditions. Bipolar Disord. 2013, 15:112-113.
54. Nutt D., Goodwin G. ECNP Summit on the future of CNS drug research in Europe 2011: report prepared for ECNP by David Nutt and Guy Goodwin. Eur. Neuropsychopharmacol.: The Journal of the European College of Neuropsychopharmacology 2011, 21:495-499.
55. O'Donnell P., Do K.Q., Arango C. Oxidative/Nitrosative stress in psychiatric disorders: are we there yet?. Schizophr. Bull. 2014, 40:960-962.
56. Offidani E., Fava G.A., Tomba E., Baldessarini R.J. Excessive mood elevation and behavioral activation with antidepressant treatment of juvenile depressive and anxiety disorders: a systematic review. Psychother. Psychosom. 2013, 82:132-141.
57. Olfson M., Blanco C., Liu S.M., Wang S., Correll C.U. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch. Gen. Psychiatry 2012, 69:1247-1256.
58. Olfson M., Blanco C., Wang S., Laje G., Correll C.U. National trends in the mental health care of children, adolescents, and adults by office-based physicians. JAMA Psychiatry 2014, 71:81-90.
59. Parellada M. Why psychogeriatrics starts right after adolescence. Eur. Child Adolesc. Psychiatry 2013, 22:391-393.
60. Patton G.C., Coffey C., Romaniuk H., Mackinnon A., Carlin J.B., Degenhardt L., Olsson C.A., Moran P. The prognosis of common mental disorders in adolescents: a 14-year prospective cohort study. Lancet 2014, 383:1404-1411.
61. Paus T., Keshavan M., Giedd J.N. Why do many psychiatric disorders emerge during adolescence? Nature reviews. Neuroscience 2008, 9:947-957.
62. Pop A.S., Gomez-Mancilla B., Neri G., Willemsen R., Gasparini F. Fragile X syndrome: a preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development. Psychopharmacology 2014, 231:1217-1226.
63. Rapoport J.L. Pediatric psychopharmacology: too much or too little?. World Psychiatry: Official Journal of the World Psychiatric Association 2013, 12:118-123.
64. Ross R.G., Hunter S.K., McCarthy L., Beuler J., Hutchison A.K., Wagner B.D., Leonard S., Stevens K.E., Freedman R. Perinatal choline effects on neonatal pathophysiology related to later schizophrenia risk. Am. J. Psychiatry 2013, 170:290-298.
65. Rubia K., Alegria A., Brinson H. Imaging the ADHD brain: disorder-specificity, medication effects and clinical translation. Expert Rev. Neurother. 2014, 14:519-538.
66. Sawa A., Seidman L.J. Is prophylactic psychiatry around the corner? Combating adolescent oxidative stress for adult psychosis and schizophrenia. Neuron 2014, 83:991-993.
67. Seese R.R., Maske A.R., Lynch G., Gall C.M. Long-term memory deficits are associated with elevated synaptic ERK1/2 activation and reversed by mGluR5 antagonism in an animal model of autism. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 2014, 39:1664-1673.
68. Sparks J.A., Duncan B.L. Outside the black box: re-assessing pediatric antidepressant prescription. J. Can. Acad. Child Adolesc. Psychiatry Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent 2013, 22:240-246.
69. Sporn A.L., Vermani A., Greenstein D.K., Bobb A.J., Spencer E.P., Clasen L.S., Tossell J.W., Stayer C.C., Gochman P.A., Lenane M.C., Rapoport J.L., Gogtay N. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J. Am. Acad. Child Adolesc. Psychiatry 2007, 46:1349-1356.
70. Stefansson H., Meyer-Lindenberg A., Steinberg S., Magnusdottir B., Morgen K., Arnarsdottir S., Bjornsdottir G., Walters G.B., Jonsdottir G.A., Doyle O.M., Tost H., Grimm O., Kristjansdottir S., Snorrason H., Davidsdottir S.R., Gudmundsson L.J., Jonsson G.F., Stefansdottir B., Helgadottir I., Haraldsson M., Jonsdottir B., Thygesen J.H., Schwarz A.J., Didriksen M., Stensbol T.B., Brammer M., Kapur S., Halldorsson J.G., Hreidarsson S., Saemundsen E., Sigurdsson E., Stefansson K. CNVs conferring risk of autism or schizophrenia affect cognition in controls. Nature 2014, 505:361-366.
71. Steinhausen H.C. A European perspective on paedo-psychiatric pharmacoepidemiology. World Psychiatry: Official Journal of the World Psychiatric Association 2013, 12:131-132.
72. Steinhausen H.C., Bisgaard C. Nationwide time trends in dispensed prescriptions of psychotropic medication for children and adolescents in Denmark. Acta Psychiatr. Scand. 2014, 129:221-231.
73. Stoyanova-Beninska V.V., Wohlfarth T., Isaac M., Kalverdijk L.J., van den Berg H., Gispen-de Wied C. The EU paediatric regulation: effects on paediatric psychopharmacology in Europe. Eur. Neuropsychopharmacol.: The Journal of the European College of Neuropsychopharmacology 2011, 21:565-570.
74. Swain R.A., Berggren K.L., Kerr A.L., Patel A., Peplinski C., Sikorski A.M. On aerobic exercise and behavioral and neural plasticity. Brain Sci. 2012, 2:709-744.
75. Swedo S.E., Leonard H.L., Rapoport J.L. The pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) subgroup: separating fact from fiction. Pediatrics 2004, 113:907-911.
76. Taylor E. Pediatric psychopharmacology: too much and too little. World Psychiatry: Official Journal of the World Psychiatric Association 2013, 12:124-125.
77. Trevathan E., Kerls S.P., Hammer A.E., Vuong A., Messenheimer J.A. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures. Pediatrics 2006, 118:e371-e378.
78. Zhao X., Leotta A., Kustanovich V., Lajonchere C., Geschwind D.H., Law K., Law P., Qiu S., Lord C., Sebat J., Ye K., Wigler M. A unified genetic theory for sporadic and inherited autism. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:12831-12836.
79. Zito J.M., Derivan A.T., Kratochvil C.J., Safer D.J., Fegert J.M., Greenhill L.L. Off-label psychopharmacologic prescribing for children: history supports close clinical monitoring. Child Adolesc. Psychiatry Ment. Health 2008, 2:24.